Median Technologies (FR:ALMDT)
:ALMDT
Want to see FR:ALMDT full AI Analyst Report?
ALMDT Stock Chart & Stats
€4.57
€0.43(9.87%)
At close: 4:00 PM EST
€4.57
€0.43(9.87%)
Day’s Range― - ―
52-Week Range€1.19 - €7.27
Previous CloseN/A
Volume91.16K
Average Volume (3M)465.96K
Market Cap
€230.87M
Enterprise Value€190.91M
Total Cash (Recent Filing)€18.41M
Total Debt (Recent Filing)€21.76M
Price to Earnings (P/E)―
Beta0.55
Next Earnings
Oct 15, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.15
Shares Outstanding48,135,193
10 Day Avg. Volume398,206
30 Day Avg. Volume465,957
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)-4.95
Price to Sales (P/S)7.45
P/FCF Ratio-9.58
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.49
Revenue Forecast (FY)€26.53M
Bulls Say, Bears Say
Bulls Say
Revenue Growth AccelerationMedian reported a meaningful revenue acceleration in 2025 (+21.5%), signaling growing demand for its imaging analytics and services. Sustained top-line growth can provide the basis for future operating leverage, help absorb fixed R&D and infrastructure costs, and validate market adoption of its clinical-trial offerings.
Focused Imaging AI Niche For Drug DevelopmentA clear, specialized business model focused on imaging analytics and AI for oncology and clinical trials creates durable competitive advantages. Deep domain expertise and tailored workflows support sticky relationships with biopharma sponsors and CROs, improving contract renewal and cross-sell potential over months.
Relatively Stable Asset BaseStable total assets provide an operational platform to deliver imaging services and support software deployment. This steadiness underpins continuity of service delivery, enables potential asset-backed financing or strategic partnerships, and reduces execution risk while the company scales commercial efforts.
Bears Say
Negative Shareholders' EquityA negative equity position materially weakens the capital structure and limits financial flexibility. It raises refinancing and covenant risk, can restrict access to non-dilutive financing, and increases the likelihood of dilutive capital raises, all of which hamper long-term strategic investments and resilience.
Consistent Operating Cash BurnPersistent negative operating cash flow means core operations do not generate sufficient cash, necessitating external funding to sustain growth. Over a multi-month horizon this elevates liquidity and dilution risk, potentially forcing management to prioritize short-term cash raises over long-term product and commercial development.
Deep, Structural UnprofitabilitySharp negative gross profit and very large net losses point to structural pricing or cost issues that undermine scalability. Without meaningful margin recovery, revenue gains may not translate to sustainable profits, keeping the company dependent on financing and delaying a path to self-sustaining operations.
Median Technologies News
ALMDT FAQ
What was Median Technologies’s price range in the past 12 months?
Median Technologies lowest stock price was €1.19 and its highest was €7.27 in the past 12 months.
What is Median Technologies’s market cap?
Median Technologies’s market cap is €230.87M.
When is Median Technologies’s upcoming earnings report date?
Median Technologies’s upcoming earnings report date is Oct 15, 2026 which is in 120 days.
How were Median Technologies’s earnings last quarter?
Median Technologies released its earnings results on Apr 23, 2026. The company reported -€0.677 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.677.
Is Median Technologies overvalued?
According to Wall Street analysts Median Technologies’s price is currently Overvalued.
Does Median Technologies pay dividends?
Median Technologies does not currently pay dividends.
What is Median Technologies’s EPS estimate?
Median Technologies’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Median Technologies have?
Median Technologies has 48,135,193 shares outstanding.
What happened to Median Technologies’s price movement after its last earnings report?
Median Technologies reported an EPS of -€0.677 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.957%.
Which hedge fund is a major shareholder of Median Technologies?
Currently, no hedge funds are holding shares in FR:ALMDT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Median Technologies
Headquartered in Valbonne, France, Median Technologies S.A. was established in 2002. This company specializes in developing and commercializing advanced software and platforms designed for medical image analysis. Its reach extends globally, serving markets in France, the United States, Canada, the United Kingdom, China, and beyond. Among its key offerings is iBiops, an innovative, AI-powered software classified as a medical device. This solution comprehensively integrates and optimizes the entire medical imaging workflow. Additionally, Median Technologies provides iSee, a service dedicated to image analysis specifically for clinical trials. Furthermore, the company delivers extensive imaging contract research organization (CRO) services. These encompass a wide range of activities, from study initiation and the management of both image and clinical data, to scientific advisory, independent reviews, image data processing, site support, and final study close-out. Solidifying its commitment to research, Median Technologies maintains a collaborative agreement with the University of California.
Technical Analysis
MAUNA KEA TECHNOLOGIES
―
Theraclion SA
―
Eurobio-Scientific SA
―
Diagnostic Medical Systems
―
Ikonisys SA
―